Robb Gary Charles 4

What Happened
Robb Gary Charles, Chief Business Officer of Corcept Therapeutics (CORT), was granted 140,000 derivative shares (reported as an award/acquisition) on February 27, 2026. The grant price is shown as $0.00 per share (i.e., an awarded grant rather than an open-market purchase or sale). The filing was made on March 3, 2026.

Key Details

• Transaction date: 2026-02-27; Form 4 filed: 2026-03-03.
• Transaction type: Grant / Award of derivative securities (code A).
• Amount: 140,000 shares; reported price: $0.00 (no cash paid at grant).
• Vesting/Exercise: Footnote F1 — vests/exercises ratably in equal installments on each monthly anniversary of Feb 27, 2026 over a four-year period, subject to continued service.
• Shares owned after transaction: not specified in the provided filing details.
• Remarks: Form notes a power of attorney was used to sign the form; no indication in this filing that it was late.

Context
This was a compensation award of derivative securities (likely options or RSUs with an exercise/vesting schedule), not a market buy or sell. Such grants are common as long-term incentive pay for executives and do not by themselves indicate immediate buying or selling sentiment. Purchases or open-market sales by insiders are typically more directly informative to investors than routine compensation grants.